Serum intact fibroblast growth factor 23 in healthy paediatric population

Abstract Introduction It is believed that fibroblast growth factor 23 (FGF23) can become an early biomarker of chronic kidney disease progression. Data on FGF23 age dependency are inconsistent. We present the results of the cross-sectional study concerning FGF23 levels in healthy Polish children. Material and methods This study was conducted in 121 children aged 0–18 years. Kidney function and intact FGF23 levels in serum were assessed. Differences between age groups and according to gender were analysed. Results The difference in FGF23 between age groups and according to gender was statistically insignificant. In the youngest and the oldest group, a trend to higher FGF23 levels was observed. FGF23 level in girls tended to be higher than boys, apart from the age group between 1 and 4 years. There was a negative correlation between eGFR and FGF23 (r = −0.26, p < 0.05) – strong in girls (r = −0.38, p < 0.05), but not in boys. In each age group, we found no significant correlation between eGFR and FGF23. Conclusions Our study supports the evidence that the FGF23 level in paediatric population is not age or sex dependent. The results can serve as a reference point under clinical conditions and for other studies on the topic.

Download Full-text

Fibroblast Growth Factor-23, Sclerostin, and Bone Microarchitecture in Patients With Osteoporotic Fractures of the Proximal Femur: A Cross-sectional Study

Journal of Clinical Densitometry ◽

10.1016/j.jocd.2014.09.003 ◽

2016 ◽

Vol 19 (2) ◽

pp. 192-201

Author(s):

Philipp K.E. Herlyn ◽

Norina Cornelius ◽

Dieter Haffner ◽

Franziska Zaage ◽

Cornelius Kasch ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Proximal Femur ◽

Bone Microarchitecture ◽

Fibroblast Growth Factor 23 ◽

Osteoporotic Fractures ◽

Cross Sectional Study ◽

Fibroblast Growth ◽

Sectional Study ◽

Cross Sectional

Download Full-text

Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study

International Journal of Molecular Sciences ◽

10.3390/ijms20092292 ◽

2019 ◽

Vol 20 (9) ◽

pp. 2292 ◽

Cited By ~ 1

Author(s):

Swati Gulati ◽

J. Michael Wells ◽

Gisel P. Urdaneta ◽

Kira Balestrini ◽

Isabel Vital ◽

...

Keyword(s):

Growth Factor ◽

Lung Function ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 23 ◽

Airway Disease ◽

Cross Sectional Study ◽

Chronic Obstructive ◽

Fibroblast Growth ◽

Cross Sectional ◽

Fgf 23

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95%CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets.

Download Full-text

Does fibroblast growth factor 23 correlates with volume status in hemodialysis patients?

Journal of Nephropathology ◽

10.15171/jnp.2019.35 ◽

2019 ◽

Vol 8 (4) ◽

pp. 35-35

Author(s):

Farzanehsadat Minoo ◽

Azam Alamdari ◽

Hamed Karimi

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 23 ◽

Volume Overload ◽

Cross Sectional Study ◽

Hemodialysis Patients ◽

Fibroblast Growth ◽

Cross Sectional ◽

Measured Volume

Introduction: Volume overload is a known risk factor for cardiovascular disease and stroke in hemodialysis patients. The use of fibroblast growth factor 23 (FGF23) as a volume overload marker has been validated in multiple studies. Objectives: This is a prospective cross-sectional study considering the association between FGF23 and bioimpedance-measured volume overload in hemodialysis patients. Patients and Methods: Bioimpedance analysis was performed on 43 hemodialysis patients at the end of hemodialysis to evaluate the remaining volume overload and serum FGF23 was measured before hemodialysis. Results: The results indicated no significant correlation between mean serum FGF23 levels and volume overload in hemodialysis patients (P=0.824). Conclusion: Although this study did not show any association between volume overload and FGF23, further studies are needed to define the role of FGF23 as a volume overload marker.

Download Full-text

Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria

Journal of Investigative Medicine ◽

10.1136/jim-2016-000142 ◽

2016 ◽

Vol 64 (6) ◽

pp. 1128-1133 ◽

Cited By ~ 11

Author(s):

Ayca Inci ◽

Funda Sari ◽

Melahat Coban ◽

Refik Olmaz ◽

Suleyman Dolu ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 23 ◽

Cross Sectional Study ◽

Healthy Controls ◽

Fibroblast Growth ◽

Cross Sectional ◽

Patients With Diabetes ◽

The Relationship

The relationship between soluble Klotho (s-Klotho) levels, fibroblast growth factor 23 (FGF23) levels, and albuminuria in patients with diabetic chronic kidney disease (CKD) remains unclear. A total of 109 patients with type 2 diabetes (mean age 61.63±9.77 years), at the outpatient clinic of the Antalya Research and Training Hospital Nephrology Unit between January and June 2014, as well as 32 healthy controls (mean age 49.53±7.32 years) were enrolled for this cross-sectional study. Patients were classified into three groups according to their urinary albumin creatinine ratio (UACR), normoalbuminuria (UACR<30 mg/g), microalbuminuria (UACR 30–300 mg/g), and macroalbuminuria (UACR>300 mg/g). The blood was analyzed for FGF23, s-Klotho, parathyroid hormone (PTH), P, Ca, creatinine, and 25-hydroxyvitamin D3 (25hD) levels. Creatinine, s-Klotho, FGF23, and PTH levels were significantly higher and 25hD levels were significantly lower in the patient group than in the healthy controls (p<0.001). Between the groups according to UACR, 1-way analysis of variance revealed statistically significant differences for creatinine (p<0.001), 25hD (p<0.001), PTH (p=0.002), Ca (p=0.002), and albumin levels (p<0.001). A statistically significant positive correlation was found between s-Klotho and FGF23 (r=0.768; p=0.001), and between FGF23 levels and UACR (r=0.768; p=0.001). In conclusion, the results of the present study suggest that s-Klotho levels are significantly elevated in patients with diabetes and s-Klotho levels decreased with increasing albumin excretion in our patients despite a reduction in estimated glomerular filtration rate.

Download Full-text

Plasma intact fibroblast growth factor 23 levels in women with bulimia nervosa: A cross-sectional pilot study

BioPsychoSocial Medicine ◽

10.1186/1751-0759-5-7 ◽

2011 ◽

Vol 5 (1) ◽

pp. 7 ◽

Cited By ~ 1

Author(s):

Makoto Otani ◽

Yoshiyuki Takimoto ◽

Junko Moriya ◽

Kazuhiro Yoshiuchi ◽

Akira Akabayashi

Keyword(s):

Pilot Study ◽

Growth Factor ◽

Bulimia Nervosa ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 23 ◽

Fibroblast Growth ◽

Cross Sectional

Download Full-text

Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients

Cardiorenal Medicine ◽

10.1159/000440984 ◽

2015 ◽

Vol 6 (1) ◽

pp. 73-82 ◽

Cited By ~ 9

Author(s):

Shahanas Chathoth ◽

Samir Al-Mueilo ◽

Cyril Cyrus ◽

Chittibabu Vatte ◽

Awatif Al-Nafaie ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Growth Factor ◽

Kidney Disease ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 23 ◽

Control Group ◽

Phosphorus Metabolism ◽

Fibroblast Growth ◽

Saudi Population ◽

Fgf23 Level

Background: The osteocyte-derived hormone, fibroblast growth factor 23 (FGF23), regulates the phosphorus metabolism and suppresses 1,25-dihydroxyvitamin D production, thereby mitigating hyperphosphatemia in patients with renal disorders. An elevated FGF23 level is suggested to be an early biomarker of altered phosphorus metabolism in the initial stages of chronic kidney disease (CKD) and acts as a strong predictor of mortality in dialysis patients. In the Saudi population, there is no report on the FGF23 level in CKD patients to date. This study aims to estimate the plasma FGF23 levels in the Saudi population and to correlate it with its clinical manifestations in order to ascertain its role in the pathogenesis of CKD patients. Methods: The FGF23 level in the plasma samples was determined using ELISA in a diverse cohort of 89 cases with stage 3-5 CKD and 100 healthy subjects. The plasma FGF23 level was correlated with other biochemical parameters. Results: The results revealed that the FGF23 level was markedly elevated among CKD patients compared to the control group, and a significant inverse correlation was observed between the FGF23 level and glomerular filtration rate. FGF23 elevation was approximately 40-fold among stage 5 patients compared to the control, while the elevation of phosphate, parathyroid hormone (PTH) and alkaline phosphatase was 2-, 3- and 8-fold in this stage, respectively. Conclusion: Elevated FGF23 levels may have a strong correlation with the disease pathogenesis. In addition, FGF23 might be a future therapeutic target to intervene against the progression of CKD as well as to increase patient survivability.

Download Full-text

Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study

BMC Nephrology ◽

10.1186/1471-2369-14-22 ◽

2013 ◽

Vol 14 (1) ◽

Cited By ~ 23

Author(s):

Masaru Nakayama ◽

Yoshiki Kaizu ◽

Masaharu Nagata ◽

Yoriko Ura ◽

Hirofumi Ikeda ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Growth Factor ◽

Kidney Disease ◽

Carotid Artery ◽

Fibroblast Growth Factor 23 ◽

Cross Sectional Study ◽

Fibroblast Growth ◽

Sectional Study ◽

Cross Sectional ◽

Carotid Artery Calcification

Download Full-text

Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women

Acta Endocrinologica ◽

10.1530/eje-11-0577 ◽

2011 ◽

Vol 165 (5) ◽

pp. 797-803 ◽

Cited By ~ 36

Author(s):

Mansi Dalal ◽

Kai Sun ◽

Anne R Cappola ◽

Luigi Ferrucci ◽

Candace Crasto ◽

...

Keyword(s):

Cardiovascular Disease ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 23 ◽

Elevated Serum ◽

Community Dwelling ◽

Fibroblast Growth ◽

Multivariable Logistic Regression Model ◽

Cross Sectional ◽

The Relationship

ObjectiveAlthough fibroblast growth factor 23 (FGF23) has been implicated in the pathogenesis of cardiovascular disease, the relationship between FGF23 and cardiovascular disease has not been well characterized in the general population. The aim of this study was to determine whether serum FGF23 is independently associated with cardiovascular disease in older community-dwelling women.Design and methodsA cross-sectional design was used to examine the relationship between serum FGF23 and cardiovascular disease. The subjects consisted of a population-based sample of 659 women, aged 70–79 years, who participated in the Women's Health and Aging Studies in Baltimore, Maryland. Prevalent cardiovascular disease (coronary heart disease, stroke, congestive heart failure, and peripheral artery disease) was assessed through diagnostic algorithms and physician adjudication.ResultsOf the 659 women, 185 (28.1%) had cardiovascular disease. Median (25th, 75th percentile) intact serum FGF23 was 34.6 (25.2, 46.2) pg/ml. The prevalence of cardiovascular disease in the lowest, middle, and highest tertile of serum FGF23 was 22.6, 24.9, and 36.7% respectively (P=0.002). Serum log FGF23 was associated with cardiovascular disease (odds ratio per 1s.d.increase=1.23, 95% confidence interval 1.17, 1.30;P<0.0001) in a multivariable logistic regression model, adjusting for age, race, smoking, education, body mass index, cognition, diabetes, hypertension, physical activity, total cholesterol, high-density lipoprotein cholesterol, and renal function.ConclusionElevated serum FGF23 concentrations are independently associated with prevalent cardiovascular disease in older community-dwelling women. Further studies are needed to elucidate the potential biological mechanisms by which FGF23 may be involved in the pathogenesis of cardiovascular disease.

Download Full-text